Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
WALTHAM, Mass., April 27, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
- Deutsche Bank Annual Health Care Conference
Tuesday, May 8, 2018 at 8:40 a.m. ET
Location: Boston, MA - Bank of America Merrill Lynch Health Care Conference
Tuesday, May 15, 2018 at 4:20 p.m. PT (7:20 p.m. ET)
Location: Las Vegas, NV
To access the live webcasts, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of each event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
